Pravastatin induces thrombomodulin expression in TNFα-treated human aortic endothelial cells by inhibiting Rac1 and Cdc42 translocation and activity

Shing Jong Lin, Yung Hsiang Chen, Feng Yen Lin, Li Yuan Hsieh, Shu Huei Wang, Chia Ying Lin, Yu Chieh Wang, Hung Hai Ku, Jaw Wen Chen, Yuh Lien Chen

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Expression of functionally active thrombomodulin (TM) on the luminal surface of endothelial cells is critical for vascular thromboresistance. The 3-hydroxyl-3-methyl coenzyme A reductase inhibitor, pravastatin, can protect the vasculature in a manner that is independent of its lipid-lowering activity. We examined the effect of pravastatin on TM expression by human aortic endothelial cells (HAECs) with subsequent tumor necrosis factor α (TNFα) stimulation and investigated the signaling pathways involved. TNFα treatment attenuated TM expression in HAECs in a time-dependent manner. Pravastatin upregulated TM levels in TNFα-treated HAECs. Specific inhibition of geranylgeranyl-transferase-I or the Rho family by GGTI-286 or TcdB, respectively, enhanced TM expression in TNFα-treated HAECs, whereas MAP kinase inhibitors, inactivation of Rho by Clostridium botulinum C3 exoenzyme, or the Rho kinase inhibitor, Y-27632, had no effect. In TNFα-treated HAECs, pravastatin inhibited Rac1 and Cdc42 activation and their translocation to the cell membrane. Blocking the transcriptional activation of NF-κB prevented the TNFα-induced downregulation of TM. The pravastatin-induced increase in TM expression in TNFα-treated HAECs was mediated through inhibition of NF-κB activation. Pravastatin regulates TM expression by inhibiting the activation of the Rho family proteins, Rac1 and Cdc42, and the transcription factor, NF-κB. The increase in endothelial TM activity in response to pravastatin constitutes a novel pleiotropic (nonlipid-related) effect of this commonly used compound and may be of clinical significance in disorders in which deficient endothelial TM plays a pathophysiological role.

Original languageEnglish
Pages (from-to)642-653
Number of pages12
JournalJournal of Cellular Biochemistry
Volume101
Issue number3
DOIs
Publication statusPublished - Jun 1 2007
Externally publishedYes

Fingerprint

Thrombomodulin
Pravastatin
Endothelial cells
Endothelial Cells
Tumor Necrosis Factor-alpha
Chemical activation
rac1 GTP-Binding Protein
cdc42 GTP-Binding Protein
human TNF protein
rho-Associated Kinases
Coenzyme A
Transferases
Hydroxyl Radical
Cell membranes
Transcriptional Activation
Blood Vessels
Oxidoreductases
Transcription Factors
Phosphotransferases
Down-Regulation

Keywords

  • Endothelial cells
  • NF-κB
  • Pravastatin
  • Rac1/Cdc42
  • Thrombomodulin

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology

Cite this

Pravastatin induces thrombomodulin expression in TNFα-treated human aortic endothelial cells by inhibiting Rac1 and Cdc42 translocation and activity. / Lin, Shing Jong; Chen, Yung Hsiang; Lin, Feng Yen; Hsieh, Li Yuan; Wang, Shu Huei; Lin, Chia Ying; Wang, Yu Chieh; Ku, Hung Hai; Chen, Jaw Wen; Chen, Yuh Lien.

In: Journal of Cellular Biochemistry, Vol. 101, No. 3, 01.06.2007, p. 642-653.

Research output: Contribution to journalArticle

Lin, Shing Jong ; Chen, Yung Hsiang ; Lin, Feng Yen ; Hsieh, Li Yuan ; Wang, Shu Huei ; Lin, Chia Ying ; Wang, Yu Chieh ; Ku, Hung Hai ; Chen, Jaw Wen ; Chen, Yuh Lien. / Pravastatin induces thrombomodulin expression in TNFα-treated human aortic endothelial cells by inhibiting Rac1 and Cdc42 translocation and activity. In: Journal of Cellular Biochemistry. 2007 ; Vol. 101, No. 3. pp. 642-653.
@article{7c9c4f587f474e6cbac0a9b87d9fbaa7,
title = "Pravastatin induces thrombomodulin expression in TNFα-treated human aortic endothelial cells by inhibiting Rac1 and Cdc42 translocation and activity",
abstract = "Expression of functionally active thrombomodulin (TM) on the luminal surface of endothelial cells is critical for vascular thromboresistance. The 3-hydroxyl-3-methyl coenzyme A reductase inhibitor, pravastatin, can protect the vasculature in a manner that is independent of its lipid-lowering activity. We examined the effect of pravastatin on TM expression by human aortic endothelial cells (HAECs) with subsequent tumor necrosis factor α (TNFα) stimulation and investigated the signaling pathways involved. TNFα treatment attenuated TM expression in HAECs in a time-dependent manner. Pravastatin upregulated TM levels in TNFα-treated HAECs. Specific inhibition of geranylgeranyl-transferase-I or the Rho family by GGTI-286 or TcdB, respectively, enhanced TM expression in TNFα-treated HAECs, whereas MAP kinase inhibitors, inactivation of Rho by Clostridium botulinum C3 exoenzyme, or the Rho kinase inhibitor, Y-27632, had no effect. In TNFα-treated HAECs, pravastatin inhibited Rac1 and Cdc42 activation and their translocation to the cell membrane. Blocking the transcriptional activation of NF-κB prevented the TNFα-induced downregulation of TM. The pravastatin-induced increase in TM expression in TNFα-treated HAECs was mediated through inhibition of NF-κB activation. Pravastatin regulates TM expression by inhibiting the activation of the Rho family proteins, Rac1 and Cdc42, and the transcription factor, NF-κB. The increase in endothelial TM activity in response to pravastatin constitutes a novel pleiotropic (nonlipid-related) effect of this commonly used compound and may be of clinical significance in disorders in which deficient endothelial TM plays a pathophysiological role.",
keywords = "Endothelial cells, NF-κB, Pravastatin, Rac1/Cdc42, Thrombomodulin",
author = "Lin, {Shing Jong} and Chen, {Yung Hsiang} and Lin, {Feng Yen} and Hsieh, {Li Yuan} and Wang, {Shu Huei} and Lin, {Chia Ying} and Wang, {Yu Chieh} and Ku, {Hung Hai} and Chen, {Jaw Wen} and Chen, {Yuh Lien}",
year = "2007",
month = "6",
day = "1",
doi = "10.1002/jcb.21206",
language = "English",
volume = "101",
pages = "642--653",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Pravastatin induces thrombomodulin expression in TNFα-treated human aortic endothelial cells by inhibiting Rac1 and Cdc42 translocation and activity

AU - Lin, Shing Jong

AU - Chen, Yung Hsiang

AU - Lin, Feng Yen

AU - Hsieh, Li Yuan

AU - Wang, Shu Huei

AU - Lin, Chia Ying

AU - Wang, Yu Chieh

AU - Ku, Hung Hai

AU - Chen, Jaw Wen

AU - Chen, Yuh Lien

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Expression of functionally active thrombomodulin (TM) on the luminal surface of endothelial cells is critical for vascular thromboresistance. The 3-hydroxyl-3-methyl coenzyme A reductase inhibitor, pravastatin, can protect the vasculature in a manner that is independent of its lipid-lowering activity. We examined the effect of pravastatin on TM expression by human aortic endothelial cells (HAECs) with subsequent tumor necrosis factor α (TNFα) stimulation and investigated the signaling pathways involved. TNFα treatment attenuated TM expression in HAECs in a time-dependent manner. Pravastatin upregulated TM levels in TNFα-treated HAECs. Specific inhibition of geranylgeranyl-transferase-I or the Rho family by GGTI-286 or TcdB, respectively, enhanced TM expression in TNFα-treated HAECs, whereas MAP kinase inhibitors, inactivation of Rho by Clostridium botulinum C3 exoenzyme, or the Rho kinase inhibitor, Y-27632, had no effect. In TNFα-treated HAECs, pravastatin inhibited Rac1 and Cdc42 activation and their translocation to the cell membrane. Blocking the transcriptional activation of NF-κB prevented the TNFα-induced downregulation of TM. The pravastatin-induced increase in TM expression in TNFα-treated HAECs was mediated through inhibition of NF-κB activation. Pravastatin regulates TM expression by inhibiting the activation of the Rho family proteins, Rac1 and Cdc42, and the transcription factor, NF-κB. The increase in endothelial TM activity in response to pravastatin constitutes a novel pleiotropic (nonlipid-related) effect of this commonly used compound and may be of clinical significance in disorders in which deficient endothelial TM plays a pathophysiological role.

AB - Expression of functionally active thrombomodulin (TM) on the luminal surface of endothelial cells is critical for vascular thromboresistance. The 3-hydroxyl-3-methyl coenzyme A reductase inhibitor, pravastatin, can protect the vasculature in a manner that is independent of its lipid-lowering activity. We examined the effect of pravastatin on TM expression by human aortic endothelial cells (HAECs) with subsequent tumor necrosis factor α (TNFα) stimulation and investigated the signaling pathways involved. TNFα treatment attenuated TM expression in HAECs in a time-dependent manner. Pravastatin upregulated TM levels in TNFα-treated HAECs. Specific inhibition of geranylgeranyl-transferase-I or the Rho family by GGTI-286 or TcdB, respectively, enhanced TM expression in TNFα-treated HAECs, whereas MAP kinase inhibitors, inactivation of Rho by Clostridium botulinum C3 exoenzyme, or the Rho kinase inhibitor, Y-27632, had no effect. In TNFα-treated HAECs, pravastatin inhibited Rac1 and Cdc42 activation and their translocation to the cell membrane. Blocking the transcriptional activation of NF-κB prevented the TNFα-induced downregulation of TM. The pravastatin-induced increase in TM expression in TNFα-treated HAECs was mediated through inhibition of NF-κB activation. Pravastatin regulates TM expression by inhibiting the activation of the Rho family proteins, Rac1 and Cdc42, and the transcription factor, NF-κB. The increase in endothelial TM activity in response to pravastatin constitutes a novel pleiotropic (nonlipid-related) effect of this commonly used compound and may be of clinical significance in disorders in which deficient endothelial TM plays a pathophysiological role.

KW - Endothelial cells

KW - NF-κB

KW - Pravastatin

KW - Rac1/Cdc42

KW - Thrombomodulin

UR - http://www.scopus.com/inward/record.url?scp=34247857446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247857446&partnerID=8YFLogxK

U2 - 10.1002/jcb.21206

DO - 10.1002/jcb.21206

M3 - Article

C2 - 17211835

AN - SCOPUS:34247857446

VL - 101

SP - 642

EP - 653

JO - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - 3

ER -